InflaRx NV IFRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day
InflaRx Announces November Investor Events
InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026
InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
InflaRx to Host Virtual Capital Markets Day
InflaRx Announces Participation in September Investor Conferences
Trading Information
- Previous Close Price
- $1.36
- Day Range
- $1.17–1.32
- 52-Week Range
- $0.80–2.95
- Bid/Ask
- $1.14 / $1.31
- Shares Outstanding
- 147.37M
- Market Cap
- $192.32M
- Volume/Avg
- 1M / 865,329
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 65
- Website
- https://www.inflarx.de
Valuation
Metric | IFRX |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.18 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | IFRX |
|---|---|
Quick Ratio | 7.00 |
Current Ratio | 7.26 |
Interest Coverage | −524.72 |
Quick Ratio
IFRX
Profitability
Metric | IFRX |
|---|---|
Return on Assets (Normalized) | −26.77% |
Return on Equity (Normalized) | −32.16% |
Return on Invested Capital (Normalized) | −34.93% |
Return on Assets
IFRX
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|wFN<Sn^ | LOCK|ms%f% | $139B | |||
| Moderna Inc MRNA | LOCK|cD<<d?> | LOCK|f< | $103B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|QPmh?^ | LOCK|?m@# | $94B | |||
| argenx SE ADR ARGX | LOCK|%@$Tyw# | LOCK|BQN | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|?#xT?c | LOCK|$z | $47B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|&>%f>%# | LOCK|%b&! | $30B | |||
| Incyte Corp INCY | LOCK|#Y@?!r% | LOCK|r%^ | $24B | |||
| BioNTech SE ADR BNTX | LOCK|!$$jZgH | LOCK|Z@ | $22B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|X^YYgmX | LOCK|!Vcg | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|!?X$>?& | LOCK|QT | $15B |
United States